Department of Neurosurgery, Lille University Hospital, rue E. Laine, 59037, Lille cedex, France.
Acta Neurochir (Wien). 2013 Jun;155(6):997-1001; discussion 1001. doi: 10.1007/s00701-013-1692-2. Epub 2013 Apr 5.
In spite of the few clinical studies regarding the occurrence of intracranial meningiomas, their prognosis in neurofibromatosis type 2 (NF2) has not been accurately assessed and their management remains controversial. This study aims to compare NF2 patients with intracranial meningiomas to those without, and consequently to identify prognostic factors in attempt to improve the management of these tumors.
This retrospective study includes a total of 80 NF2 patients followed at Lille Hospital Center between 1987 and 2011. The diagnosis of NF2 was confirmed either because the patient met the Manchester criteria or by the presence of genetic mutation. Clinical, radiological and genetic data were retrospectively recorded and analyzed. Patients underwent annual cranial and spinal MRI. Both location and size of each tumor were reported.
The mean follow-up period was 8.8 years (range 1-24 years; SD: ±0.8) and the mean age at diagnosis was 27.2 years (range 6-73 years; SD: ±1.7). Among all patients, 34 harbored intracranial meningiomas. Patients with intracranial meningiomas had a higher number of intracranial schwannomas, spinal tumors and cutaneous tumors (p < 0.05). They underwent more surgical procedures (p < 0.012). Twenty five intracranial meningiomas were surgically removed in 17 patients. The decision to perform surgery was taken in 10 cases for symptomatic tumors and in 15 cases for growing asymptomatic tumors determined by radiology. The histological analysis found a high rate of fibroblastic, transitional or grade 2 meningiomas preferentially located at the cerebri falx.
Intracranial meningiomas are common in NF2. They are associated with poor prognosis factors. Clinical and radiological monitoring could lead to early treatment of these tumors both when clinical symptoms are present and in case of proven radiological evolution, and thus trying to maintain a favorable functional prognosis for as long as possible.
尽管关于颅内脑膜瘤发生的临床研究较少,但神经纤维瘤病 2 型(NF2)患者的预后尚未得到准确评估,其治疗仍存在争议。本研究旨在比较 NF2 伴颅内脑膜瘤患者与不伴颅内脑膜瘤患者,并确定预后因素,以期改善这些肿瘤的治疗效果。
本回顾性研究共纳入 80 例于 1987 年至 2011 年在里尔医院中心接受治疗的 NF2 患者。NF2 的诊断通过患者符合曼彻斯特标准或存在基因突变来确定。回顾性记录并分析了临床、影像学和遗传学数据。患者每年接受颅脊柱 MRI 检查。报告了每个肿瘤的位置和大小。
平均随访时间为 8.8 年(范围为 1-24 年;标准差:±0.8),诊断时的平均年龄为 27.2 岁(范围为 6-73 岁;标准差:±1.7)。所有患者中,34 例存在颅内脑膜瘤。颅内脑膜瘤患者颅内听神经瘤、脊髓肿瘤和皮肤肿瘤更多(p<0.05),接受的手术治疗更多(p<0.012)。17 例患者中,25 例颅内脑膜瘤通过手术切除。10 例手术是为了治疗有症状的肿瘤,15 例手术是为了治疗影像学上确定的生长性无症状肿瘤。组织学分析发现,纤维母细胞型、过渡型或 2 级脑膜瘤发生率较高,这些肿瘤优先位于大脑镰。
颅内脑膜瘤在 NF2 中很常见。它们与不良预后因素有关。临床和影像学监测可以在出现临床症状时及早治疗这些肿瘤,也可以在影像学证实进展时进行治疗,从而尽可能长时间地保持良好的功能预后。